ATE516803T1 - Aryl-spirohydantoin-cgrp-rezeptor-antagonisten - Google Patents
Aryl-spirohydantoin-cgrp-rezeptor-antagonistenInfo
- Publication number
- ATE516803T1 ATE516803T1 AT04719322T AT04719322T ATE516803T1 AT E516803 T1 ATE516803 T1 AT E516803T1 AT 04719322 T AT04719322 T AT 04719322T AT 04719322 T AT04719322 T AT 04719322T AT E516803 T1 ATE516803 T1 AT E516803T1
- Authority
- AT
- Austria
- Prior art keywords
- aryl
- receptor antagonists
- cgrp receptor
- spirohydantoin
- compounds
- Prior art date
Links
- 108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 title abstract 2
- QAHZIGHCEBUNGT-QMGFNSACSA-N (5r,6s,7s,8r,9r)-6,7,8-trihydroxy-9-(hydroxymethyl)-1,3-diazaspiro[4.5]decane-2,4-dione Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)C[C@]11C(=O)NC(=O)N1 QAHZIGHCEBUNGT-QMGFNSACSA-N 0.000 title 1
- 102000008323 calcitonin gene-related peptide receptor activity proteins Human genes 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 abstract 2
- 102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 abstract 2
- 102000014468 Calcitonin Gene-Related Peptide Receptors Human genes 0.000 abstract 1
- 208000006561 Cluster Headache Diseases 0.000 abstract 1
- 206010019233 Headaches Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 208000018912 cluster headache syndrome Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 231100000869 headache Toxicity 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45491703P | 2003-03-14 | 2003-03-14 | |
| PCT/US2004/007686 WO2004082678A1 (en) | 2003-03-14 | 2004-03-10 | Aryl spirohydantoin cgrp receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE516803T1 true ATE516803T1 (de) | 2011-08-15 |
Family
ID=33029928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04719322T ATE516803T1 (de) | 2003-03-14 | 2004-03-10 | Aryl-spirohydantoin-cgrp-rezeptor-antagonisten |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7189722B2 (de) |
| EP (1) | EP1605936B1 (de) |
| JP (1) | JP4673296B2 (de) |
| AT (1) | ATE516803T1 (de) |
| AU (1) | AU2004222328B2 (de) |
| CA (1) | CA2518843A1 (de) |
| WO (1) | WO2004082678A1 (de) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7842808B2 (en) | 2002-06-05 | 2010-11-30 | Bristol-Myers Squibb Company | Anti-migraine spirocycles |
| US7220862B2 (en) | 2002-06-05 | 2007-05-22 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
| CA2519515A1 (en) * | 2003-03-14 | 2004-10-14 | Merck & Co., Inc. | Benodiazepine spirohydantoin cgrp receptor antagonists |
| TW200524601A (en) | 2003-12-05 | 2005-08-01 | Bristol Myers Squibb Co | Heterocyclic anti-migraine agents |
| TW200533398A (en) | 2004-03-29 | 2005-10-16 | Bristol Myers Squibb Co | Novel therapeutic agents for the treatment of migraine |
| US7659300B2 (en) * | 2004-09-08 | 2010-02-09 | Merck Sharp & Dohme Corp. | Monocyclic anilide spirolactam CGRP receptor antagonists |
| EP1794133B1 (de) * | 2004-09-09 | 2011-12-14 | Merck Sharp & Dohme Corp. | Arylspirolactamverbindungen als antagonisten des cgrp-rezeptors |
| CA2579847A1 (en) | 2004-09-13 | 2006-03-23 | Merck & Co., Inc. | Bicyclic anilide spirolactam cgrp receptor antagonists |
| US7750010B2 (en) * | 2004-09-13 | 2010-07-06 | Merck Sharp & Dohme Corp. | Tricyclic anilide spirohydantion CGRP receptor antagonists |
| US7384931B2 (en) | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
| US7384930B2 (en) | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
| US7449586B2 (en) | 2004-12-03 | 2008-11-11 | Bristol-Myers Squibb Company | Processes for the preparation of CGRP-receptor antagonists and intermediates thereof |
| US7834007B2 (en) | 2005-08-25 | 2010-11-16 | Bristol-Myers Squibb Company | CGRP antagonists |
| EP3069731A1 (de) | 2005-11-14 | 2016-09-21 | Labrys Biologics Inc. | Antagonistische antikörper gegen calcitoningen-assoziiertes peptid und verfahren damit |
| WO2007061677A2 (en) * | 2005-11-18 | 2007-05-31 | Merck & Co., Inc. | Spirolactam aryl cgrp receptor antagonists |
| AU2006316644B2 (en) | 2005-11-18 | 2011-11-10 | Merck Sharp & Dohme Corp. | Spirohydantoin tricyclic CGRP receptor antagonists |
| JP2009515971A (ja) | 2005-11-18 | 2009-04-16 | メルク エンド カムパニー インコーポレーテッド | スピロヒダントインアリールｃｇｒｐ受容体アンタゴニスト |
| AU2006316642A1 (en) * | 2005-11-18 | 2007-05-31 | Merck Sharp & Dohme Corp. | Spirolactam tricyclic CGRP receptor antagonists |
| AU2007284994B2 (en) * | 2006-05-09 | 2010-04-22 | Merck Sharp & Dohme Corp. | Substituted spirocyclic CGRP receptor antagonists |
| DE602007006961D1 (de) * | 2006-07-21 | 2010-07-15 | Vertex Pharma | Cgrp-rezeptorantagonisten |
| US7951795B2 (en) * | 2006-12-08 | 2011-05-31 | Merck Sharp & Dohme Corp. | Constrained spirocyclic compounds as CGRP receptor antagonists |
| US8372859B2 (en) * | 2007-04-11 | 2013-02-12 | Merck, Sharp & Dohme Corp. | CGRP receptor antagonists with tertiary amide, sulfonamide, carbamate and urea end groups |
| AU2008241488A1 (en) * | 2007-04-16 | 2008-10-30 | Merck Sharp & Dohme Corp. | Bicyclic anilide heterocyclic CGRP receptor antagonists |
| WO2008130524A1 (en) * | 2007-04-16 | 2008-10-30 | Merck & Co., Inc. | Aryl heterocyclic cgrp receptor antagonists |
| CA2689217C (en) * | 2007-06-05 | 2016-02-16 | Merck & Co., Inc. | Carboxamide heterocyclic cgrp receptor antagonists |
| WO2008153852A1 (en) * | 2007-06-07 | 2008-12-18 | Merck & Co., Inc. | Tricyclic anilide heterocyclic cgrp receptor antagonists |
| RU2522493C2 (ru) | 2008-03-04 | 2014-07-20 | Пфайзер Лимитед | Способы лечения хронической боли |
| CA2735821A1 (en) * | 2008-09-08 | 2010-03-11 | Merck Sharp & Dohme Corp. | Monocyclic amide cgrp receptor antagonists |
| US7815880B2 (en) * | 2008-09-30 | 2010-10-19 | Calera Corporation | Reduced-carbon footprint concrete compositions |
| CN102740884A (zh) | 2009-08-28 | 2012-10-17 | 瑞纳神经科学公司 | 通过施用针对降钙素基因相关肽的拮抗性抗体来治疗内脏痛的方法 |
| CN107827982B (zh) | 2011-05-20 | 2021-07-06 | H.伦德贝克公司 | 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途 |
| TWI705825B (zh) | 2011-05-20 | 2020-10-01 | 美商艾爾德生物控股有限責任公司 | 抗降血鈣素基因相關胜肽（ａｎｔｉ－ｃｇｒｐ）或抗降血鈣素基因相關胜肽受器（ａｎｔｉ－ｃｇｒｐ－ｒ）抗體或抗體片段治療或預防慢性及急性型腹瀉之用途 |
| PE20141787A1 (es) | 2011-05-20 | 2014-12-07 | Alderbio Holdings Llc | Composiciones anti-cgrp y uso de las mismas |
| EP2846798B1 (de) * | 2012-05-09 | 2018-04-04 | Merck Sharp & Dohme Corp. | Aliphatische spirolactam-cgrp-rezeptorantagonisten |
| US20170114122A1 (en) | 2015-10-23 | 2017-04-27 | Alderbio Holdings Llc | Regulation of glucose metabolism using anti-cgrp antibodies |
| AU2015230933B2 (en) | 2014-03-21 | 2020-08-13 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| CN109952314A (zh) | 2016-09-23 | 2019-06-28 | 泰瓦制药国际有限公司 | 治疗难治性偏头痛 |
| EP3366286A1 (de) | 2017-02-22 | 2018-08-29 | Johannes Keller | Verbindungen zur behandlung von sepsis |
| CA3061653C (en) * | 2017-05-15 | 2022-09-06 | Eli Lilly And Company | Cgrp receptor antagonists |
| AR111665A1 (es) * | 2017-05-15 | 2019-08-07 | Lilly Co Eli | Derivados de 3-metil-pirrolidina-2,5-diona útiles como antagonistas del receptor cgrp |
| WO2020146527A1 (en) | 2019-01-08 | 2020-07-16 | Alder Biopharmaceuticals, Inc. | Acute treatment and rapid treatment of headache using anti-cgrp antibodies |
| CA3077973A1 (en) | 2020-04-06 | 2021-10-06 | H. Lundbeck A/S | Treatment of most bothersome symptom (mbs) associated with migraine using anti-cgrp antibodies |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3561198D1 (en) | 1984-03-23 | 1988-01-28 | Pfizer | Spiro-indenes and spiro-1,2-dihydro-naphthalenes for treatment of diabetic complications |
| JP3449084B2 (ja) * | 1995-12-25 | 2003-09-22 | 富士レビオ株式会社 | ヒダントイン誘導体 |
| ATE394400T1 (de) * | 2003-03-14 | 2008-05-15 | Merck & Co Inc | Bicyclische anilidspirohydantoine als cgrp- rezeptorantagonisten |
| EP1606264B1 (de) * | 2003-03-14 | 2012-05-02 | Merck Sharp & Dohme Corp. | Monocyclische anilidspirohydantoine als cgrp-rezeptorantagonisten |
-
2004
- 2004-03-10 AU AU2004222328A patent/AU2004222328B2/en not_active Ceased
- 2004-03-10 WO PCT/US2004/007686 patent/WO2004082678A1/en not_active Ceased
- 2004-03-10 AT AT04719322T patent/ATE516803T1/de not_active IP Right Cessation
- 2004-03-10 EP EP04719322A patent/EP1605936B1/de not_active Expired - Lifetime
- 2004-03-10 CA CA002518843A patent/CA2518843A1/en not_active Abandoned
- 2004-03-10 US US10/547,227 patent/US7189722B2/en not_active Expired - Lifetime
- 2004-03-10 JP JP2006507140A patent/JP4673296B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2518843A1 (en) | 2004-09-30 |
| US7189722B2 (en) | 2007-03-13 |
| JP2006520388A (ja) | 2006-09-07 |
| WO2004082678A1 (en) | 2004-09-30 |
| EP1605936A1 (de) | 2005-12-21 |
| US20060189593A1 (en) | 2006-08-24 |
| AU2004222328A1 (en) | 2004-09-30 |
| JP4673296B2 (ja) | 2011-04-20 |
| AU2004222328B2 (en) | 2009-10-08 |
| EP1605936B1 (de) | 2011-07-20 |
| EP1605936A4 (de) | 2008-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE516803T1 (de) | Aryl-spirohydantoin-cgrp-rezeptor-antagonisten | |
| ATE535514T1 (de) | Carboxamid-spirohydantoin-cgrp-rezeptor- antagonisten | |
| EP1606286A4 (de) | Benzodiazepinspirohydantoine als cgrp-rezeptorantagonisten | |
| ATE394400T1 (de) | Bicyclische anilidspirohydantoine als cgrp- rezeptorantagonisten | |
| ATE556060T1 (de) | Monocyclische anilidspirohydantoine als cgrp- rezeptorantagonisten | |
| JO2355B1 (en) | Hereditary calcitonin polypeptide receptor antagonists | |
| NO20072435L (no) | CGRP-reseptorantagonister | |
| DE602005020655D1 (de) | Carboxamid-spirolactam-cgrp-rezeptor-antagonisten | |
| ATE464305T1 (de) | Bicyclische anilidspirolactame als antagonisten des cgrp-rezeptors | |
| ATE466860T1 (de) | Cgrp-rezeptorantagonisten | |
| ATE537170T1 (de) | Cgrp-rezeptorantagonisten | |
| DE602007008434D1 (de) | Rezeptoren | |
| NO20092470L (no) | Substituerte diazepanforbindelser som orexinreseptorantagonister | |
| WO2005000807A3 (en) | Benzodiazepine cgrp receptor antagonists | |
| EP1794133A4 (de) | Arylspirolactamverbindungen als antagonisten des cgrp-rezeptors | |
| ATE463245T1 (de) | Tricyclische anilid-spirohydantoin-cgrp- rezeptorantagonisten | |
| ATE493412T1 (de) | Spirohydantoin-aryl-cgrp-rezeptorantagonisten | |
| ATE518852T1 (de) | Tricyclische anilid-spirohydantoin-cgrp- rezeptorantagonisten | |
| ATE503755T1 (de) | Cgrp-rezeptorantagonisten | |
| ATE507880T1 (de) | Cgrp-rezeptorantagonisten | |
| ATE466853T1 (de) | Cgrp-rezeptorantagonisten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |